重大事件
外國發行人報告
6-K
2026-06-25
InMode 提交6-K 披露遭專利侵權訴訟及ITC調查 涉Morpheus8產品
AI 繁中摘要
📄 **InMode Ltd. 提交 6-K 表格：披露專利侵權訴訟及 ITC 調查**
InMode Ltd.（納斯達克代碼：INMD）於 2026 年 6 月 25 日提交 6-K 表格，披露一宗由 Serendia LLC 在 2026 年 6 月 22 日於美國加州中區聯邦地方法院提起的專利侵權訴訟。Serendia 指控 InMode 及旗下子公司 Invasix Inc. 進口及銷售特定微針皮膚治療設備（包括 Morpheus8 系列產品及相關平台與主機）侵犯其四項美國專利，要求未指明金額的賠償金，並尋求禁令阻止涉案產品的進口與銷售。
此外，Serendia 已向美國國際貿易委員會（ITC）提交平行投訴，要求發布有限排除令（禁止侵權產品進口）及停止銷售令（禁止出售美國庫存中的對應產品）。
InMode 表示，案件處於初步階段，尚未正式答辯。公司否認侵權指控，並主張 Serendia 的專利無效，將積極為兩項投訴進行抗辯。截至申報日，管理層無法合理估計若最終判決不利可能導致的損失範圍，因此未在財務報表中計提任何相關負債。
⚖️ **對投資者的潛在影響**：此訴訟及 ITC 調查可能對 InMode 旗下 Morpheus8 產品線在美國市場的銷售及供應鏈構成不確定性。若最終禁令生效，或需支付巨額賠償金，將影響公司收入及盈利能力。投資者應關注案件進展及 InMode 的防禦策略，特別是 ITC 調查的初步裁決時間表（通常較地方法院迅速）。短期內股價或受訴訟消息波動，但公司現金儲備充足，具備抗辯能力。
展開英文正文
6-K 1 zk2635614.htm 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2026 INMODE LTD. (Exact name of registrant as specified in its charter) Tavor Building, Sha’ar Yokneam P.O. Box 533 Yokneam 2069206 Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐ Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: Yes ☐ No ☒ On June 22, 2026, Serendia LLC (“Serendia”) filed a complaint against InMode Ltd. (the “Company”) and its wholly-owned subsidiary, Invasix Inc., in the United States District Court for the Central District of California. The lawsuit alleges that the Company infringed four U.S. patents by importing and selling certain microneedling dermatological treatment devices, including the Morpheus8 products and associated platforms and consoles. The lawsuit seeks unspecified damages and an injunction against the importation and sale of the accused products. This matter is in its preliminary stages, and the Company has not yet responded to the complaint. As of the date of this filing, the Company is unable to estimate a range of loss, if any, that could result if there were to be an adverse final decision in this matter, and an estimated liability has not been recorded in the Company’s financial statements. Serendia also filed a parallel complaint with the International Trade Commission, seeking a limited exclusion order barring the importation of the products subject to the infringement claim and a cease-and-desist order barring the sale of any corresponding U.S. inventory. The Company intends to deny the allegations of infringement, assert that Serendia’s patents are invalid, and vigorously defend against the claims in both complaints. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. InMode Ltd. By: /s/ Moshik Itzkovich Moshik Itzkovich June 25, 2026 Chief Financial Officer